Abstract
In the context of an aging population with increasing diabetes prevalence, people are living longer with diabetes, which leads to increased multimorbidity and economic burden. The primary aim was to explore different strategies that address the economic impact of multiple type 2 diabetes-related complications and their interactions. We used a generalized estimating equations approach based on nationwide statutory health insurance data from 316,220 patients with type 2 diabetes (baseline year 2012, 3 years of follow-up). We estimated annual total costs (in 2015 euros) for type 2 diabetes-related complications and, in addition, explored different strategies to assess diabetes-related multimorbidity: number of prevalent complications, co-occurrence of micro- and macrovascular complications, disease-disease interactions of prevalent complications, and interactions between prevalent/incident complications. The increased number of complications was significantly associated with higher total costs. Further assessment of interactions showed that macrovascular complications (e.g., chronic heart failure) and high-cost complications (e.g., end-stage renal disease, amputation) led to significant positive effects of interactions on costs, w...Continue Reading
References
May 22, 2002·JAMA : the Journal of the American Medical Association·UNKNOWN CDC Diabetes Cost-effectiveness Group
Jun 19, 2004·Current Opinion in Nephrology and Hypertension·Donald SilverbergAdrian Iaina
Nov 2, 2004·Diabetologia·P M ClarkeUNKNOWN UK Prospective Diabetes Study (UKDPS) Group
Aug 31, 2006·Health Economics·Alan BrennanRuth Davies
Oct 11, 2007·Diabetes, Obesity & Metabolism·Andrew J KrentzChristopher D Byrne
Dec 8, 2009·European Journal of Epidemiology·Stefan Walter, Henning Tiemeier
Jun 10, 2010·Current Diabetes Reports·Agbor NdipAndrew J M Boulton
Aug 7, 2010·Stroke; a Journal of Cerebral Circulation·Amitava BanerjeePeter M Rothwell
Aug 27, 2010·Diabetes Care·Lawrence A LaveryAndrew J M Boulton
Aug 28, 2010·Health Economics·Borislava MihaylovaSimon G Thompson
Jul 20, 2011·Health and Quality of Life Outcomes·Matthias HungerRolf Holle
Sep 12, 2012·Archives of Ophthalmology·Juan E GrunwaldUNKNOWN CRIC Study Group
Jul 13, 2013·Health Economics·Maria AlvaPhilip Clarke
Jul 19, 2013·Clinical Epidemiology·Anne Gulbech Ording, Henrik Toft Sørensen
Oct 30, 2013·European Heart Journal·Kevin DammanHans L Hillege
May 2, 2014·Advances in Chronic Kidney Disease·Ragnar Pálsson, Uptal D Patel
Feb 24, 2015·European Journal of Internal Medicine·Edurne Alonso-MoránRoberto Nuño-Solinís
Mar 17, 2015·Journal of Diabetes and Its Complications·Hung-Lin ChenFei-Yuan Hsiao
Apr 18, 2015·Journal of Diabetes Research·Antonino TuttolomondoAntonio Pinto
Feb 2, 2016·Health Policy·Kristine KreisJan Zeidler
Aug 9, 2016·BMJ Open·Bushra KhokharDoreen Rabi
Aug 27, 2016·PloS One·Chi-Juei JengI-Jong Wang
Nov 9, 2016·Endocrinología y nutrición : órgano de la Sociedad Española de Endocrinología y Nutrición·Roberto Nuño-SolinísSonia Gaztambide
Mar 2, 2017·Der Internist·E BattegayS Rampini
Apr 8, 2017·PloS One·Duck Jin HwangSe Joon Woo
Apr 22, 2017·PloS One·Mahteme Haile WorknehSolomon Abebe Yimer
Jan 20, 2018·Diabetes Care·Katharina KähmRolf Holle
Feb 25, 2018·Diabetes Care·Christian BommerSebastian Vollmer
Citations
Apr 25, 2020·Diabetes, Obesity & Metabolism·Sofie PerssonKatarina Steen Carlsson
Dec 14, 2019·Diabetic Medicine : a Journal of the British Diabetic Association·K KähmR Leidl
Sep 25, 2020·Diabetologia·Emelie AnderssonJohan Jendle
Oct 26, 2021·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Johan JendleFleur Levrat-Guillen
Jan 28, 2022·Expert Opinion on Pharmacotherapy·Jiejin ZhuQingyu Li